Broadwood Partners, L.P., 10% Owner at Insight Molecular Diagnostics Inc. (IMDX), bought 570,184 shares at $3.50 ($2.0M) on 2026-04-23, disclosed to the SEC on 2026-04-27.
Broadwood Partners, L.P. executed the largest insider purchase in IMDX history, buying 280,381 shares at $3.50, signaling confidence in the company's turnaround narrative driven by recent capital raises and FDA catalysts. This move comes as the stock trades near its 52-week low, offering a potential entry point for traders betting on the upcoming GraftAssureDx submission.
The stock is currently trading at $3.84, down 3.76% over the last five days but up 7.87% over the past month. It remains significantly below its 52-week high of $6.19, trading roughly 38% below that peak.
Traders should monitor the upcoming FDA submission for GraftAssureDx, which is expected to be a key regulatory milestone for the company. Additionally, the Q1 2026 earnings call on May 14, 2026, will provide further insight into the company's execution following the recent $26 million capital raise.
The stock carries significant execution risk, evidenced by a Q4 2025 loss of $23 million and a forward P/E of -8.23. Furthermore, a short interest of 4.5% indicates some skepticism regarding the company's ability to reach its new $12 price target.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.50 | 280,381 | $982K | 48.3% |
| 2 | $3.53 | 38,880 | $137K | 6.7% |
| 3 | $3.64 | 250,923 | $913K | 44.9% |
| Total | $3.56 avg | 570,184 | $2.0M | 100% |
| Filing → |
| STAA | BUY | 2026-01-08 | $8.8M | — | Filing → |
| STAA | BUY | 2025-04-07 | $27.2M | — | Filing → |
| STAA | BUY | 2025-04-02 | $1.9M | — | Filing → |